Key Takeaways
- In Portugal, following drug decriminalization in 2001, overdose deaths decreased by 80% from 80 in 2001 to 16 in 2012
- Portugal's overdose mortality rate fell from 28 per million in 2001 to 6 per million by 2019 after decriminalization
- In Oregon post-Measure 110 decriminalization (2021), fentanyl overdose deaths rose 44% from 2020 to 2021 but treatment referrals increased via deflection programs
- Portugal's drug treatment entry rates increased 147% from 1,400 in 2001 to 3,463 in 2008 post-decriminalization
- Post-decriminalization, Portugal saw 18% of problem drug users in treatment by 2019 vs 6% pre-2001
- Oregon Measure 110 funded $302M in behavioral health grants, leading to 6,000+ treatment beds by 2023
- Drug possession arrests in Portugal dropped 60% from 14,000 in 2000 to 5,000-6,000 annually post-2001 decriminalization
- Post-decriminalization Portugal saw lifetime criminal records for drugs fall 99% for youth under 18
- Oregon post-Measure 110 (2021): personal possession arrests declined 65% from 2020 levels
- In Portugal post-decriminalization, healthcare spending on drug treatment rose from €12M to €75M annually by 2019, saving €18,000 per avoided HIV case
- Oregon Measure 110 reallocated $1.4B cannabis tax over 10 years to addiction services
- Portugal post-2001: criminal justice drug costs fell €18M/year, offset by €10M treatment rise, net savings
- Lifetime drug use prevalence in Portugal remained stable at 12% adults post-2001 decriminalization vs rising EU trends
- Portugal youth (15-24) cannabis use steady at 10-12% 2001-2019 post-decrim
- Oregon post-Measure 110: adult past-year drug use unchanged at 35%
Portugal's decriminalization reduced overdoses and disease, but Oregon struggled with implementation.
Criminal Justice Impacts
Criminal Justice Impacts Interpretation
Drug Use Prevalence and Patterns
Drug Use Prevalence and Patterns Interpretation
Economic Costs and Savings
Economic Costs and Savings Interpretation
Overdose and Mortality Rates
Overdose and Mortality Rates Interpretation
Treatment Access and Utilization
Treatment Access and Utilization Interpretation
Sources & References
- Reference 1CATOcato.orgVisit source
- Reference 2OREGONoregon.govVisit source
- Reference 3TRANSFORMDRUGStransformdrugs.orgVisit source
- Reference 4CDCcdc.govVisit source
- Reference 5EMCDDAemcdda.europa.euVisit source
- Reference 6DRUGPOLICYdrugpolicy.orgVisit source
- Reference 7VCHvch.caVisit source
- Reference 8SICADsicad.ptVisit source
- Reference 9CATDIRcatdir.loc.govVisit source
- Reference 10PUBLICHEALTHpublichealth.oregon.govVisit source
- Reference 11EUDAeuda.europa.euVisit source
- Reference 12OREGONLIVEoregonlive.comVisit source
- Reference 13DRUGPOLICYFACTSdrugpolicyfacts.orgVisit source
- Reference 14NCBIncbi.nlm.nih.govVisit source
- Reference 15NIDAnida.nih.govVisit source
- Reference 16GATEWAYgateway.euro.who.intVisit source
- Reference 17OPBopb.orgVisit source
- Reference 18ECec.europa.euVisit source
- Reference 19DPHHSdphhs.mt.govVisit source
- Reference 20DRUGPOLICYALLIANCEdrugpolicyalliance.orgVisit source
- Reference 21OREGONHEALTHNEWSoregonhealthnews.comVisit source
- Reference 22STATESMANJOURNALstatesmanjournal.comVisit source
- Reference 23PORTLANDOREGONportlandoregon.govVisit source
- Reference 24BCSTATSbcstats.shinyapps.ioVisit source
- Reference 25KOINkoin.comVisit source






